Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04191681 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) Study

Study acronym: SEAL-IT
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 7, 2021 (before its estimated March 2022 completion). Its status may not reflect the trial's current state.

Record History

  1. Re-verified, no change to tracked fieldsv3
  2. Primary completion date: Mar 2020 to Mar 2022
    • Study completion date: Dec 2020 to Dec 2022
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The Cleveland Clinic
212 trials monitored
See 33 trials at risk
Heart Disease
8,786 trials monitored
See 412 trials at risk
Heart Failure
1,995 trials monitored
See 111 trials at risk
The purpose of the study is to evaluate how well tolerated and effective an angiotensin receptor-neprilysin inhibitor (sacubitril-valsartan) is in patients with contemporary durable continuous flow left ventricular assist device (CF-LVAD) implantation compared to usual care oral vasodilator therapy.
Trial Details
NCT Number NCT04191681
Lead Sponsor The Cleveland Clinic
Conditions
(from sponsor)		 Stage D Heart Failure
Related terms Heart Failure
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov